Literature DB >> 24825741

Triggering factors of primary care costs in the years following type 2 diabetes diagnosis in Mexico.

Angélica Castro-Ríos1, Armando Nevárez-Sida2, María Teresa Tiro-Sánchez3, Niels Wacher-Rodarte4.   

Abstract

BACKGROUND AND AIMS: Diabetes represents a high epidemiological and economic burden worldwide. The cost of diabetes care increases slowly during early years, but it accelerates once chronic complications set in. There is evidence that adequate control may delay the onset of complications. Management of diabetes falls almost exclusively into primary care services until chronic complications appear. Therefore, primary care is strategic for reducing the expedited growth of costs. The objective of this study was to identify predictors of primary care costs in patients without complications in the years following diabetes diagnosis.
METHODS: Direct medical costs for primary care were determined from the perspective of public health services provider. Information was obtained from medical records of 764 patients. Microcosting and average cost techniques were combined. A generalized linear regression model was developed including characteristics of patients and facilities. Primary health care costs for different patient profiles were estimated.
RESULTS: The mean annual primary care cost was USD$465.1. Gender was the most important predictor followed by weight status, insulin use, respiratoty infections, glycemic control and dyslipidemia. A gap in costs was observed between genders; women make greater use of resources (42.1% on average). Such differences are reduced with obesity (18.1%), overweight (22.8%), respiratory infection (20.8%) and age >80 years (26.8%). Improving glycemic control shows increasing costs but at decreasing rates.
CONCLUSIONS: Modifiable factors (glycemic control, weight status and comorbidities) drive primary care costs the first 10 years. Those factors had a larger effect in costs for males than in for females.
Copyright © 2014 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Direct costs; Predictors; Primary care; Resource use; Type 2 diabetes

Mesh:

Year:  2014        PMID: 24825741     DOI: 10.1016/j.arcmed.2014.05.002

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  4 in total

1.  Metformin Induces Cell Cycle Arrest, Reduced Proliferation, Wound Healing Impairment In Vivo and Is Associated to Clinical Outcomes in Diabetic Foot Ulcer Patients.

Authors:  Fatima Ochoa-Gonzalez; Alberto R Cervantes-Villagrana; Julio C Fernandez-Ruiz; Hilda S Nava-Ramirez; Adriana C Hernandez-Correa; Jose A Enciso-Moreno; Julio E Castañeda-Delgado
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

2.  Obesity in Mexico: prevalence, comorbidities, associations with patient outcomes, and treatment experiences.

Authors:  Marco D DiBonaventura; Henrik Meincke; Agathe Le Lay; Janine Fournier; Erik Bakker; Allison Ehrenreich
Journal:  Diabetes Metab Syndr Obes       Date:  2017-12-22       Impact factor: 3.168

3.  Dyslipidemia: The untreated metabolic dysfunction in people with type 2 diabetes in Latin America. ARETAEUS study outcomes.

Authors:  Juan José Gagliardino; Rosario Arechavaleta; Freddy Goldberg Eliaschewitz; Kristy Iglay; Kimberly Brodovicz; Claudio D Gonzalez; Shengsheng Yu; R Ravi Shankar; Olaf Heisel; Paul Keown; Kaan Tunceli
Journal:  J Clin Transl Endocrinol       Date:  2019-01-25

4.  Genetic polymorphisms of antioxidant enzymes CAT and SOD affect the outcome of clinical, biochemical, and anthropometric variables in people with obesity under a dietary intervention.

Authors:  César Hernández-Guerrero; Alicia Parra-Carriedo; Diana Ruiz-de-Santiago; Oscar Galicia-Castillo; Mario Buenrostro-Jáuregui; Carmen Díaz-Gutiérrez
Journal:  Genes Nutr       Date:  2018-01-08       Impact factor: 5.523

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.